See more : OncoZenge AB (publ) (ONCOZ.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Checkmate Pharmaceuticals, Inc. (CMPI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Checkmate Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- MPIL Corporation Limited (MPILCORPL.BO) Income Statement Analysis – Financial Results
- Nippon Coke & Engineering Company, Limited (3315.T) Income Statement Analysis – Financial Results
- Shanghai Industrial Holdings Limited (SGHIF) Income Statement Analysis – Financial Results
- Asian Sea Corporation Public Company Limited (ASIAN.BK) Income Statement Analysis – Financial Results
- Jinli Group Holdings Limited (8429.TW) Income Statement Analysis – Financial Results
Checkmate Pharmaceuticals, Inc. (CMPI)
About Checkmate Pharmaceuticals, Inc.
Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. As of May 27, 2022, Checkmate Pharmaceuticals, Inc. operates as a subsidiary of Regeneron Pharmaceuticals, Inc.
| Metric | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 45.82M | 26.72M | 24.25M | 18.17M |
| General & Administrative | 15.65M | 10.19M | 4.64M | 2.82M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.65M | 10.19M | 4.64M | 2.82M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 61.47M | 36.90M | 28.89M | 20.99M |
| Cost & Expenses | 61.47M | 36.90M | 28.89M | 20.99M |
| Interest Income | 100.00K | 79.00K | 197.00K | 180.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 66.00K | 188.00K | 597.00K | 180.00K |
| EBITDA | -61.34M | -36.72M | -28.29M | -20.81M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -61.41M | -36.90M | -28.89M | -20.99M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 0.00 | -4.00K | 597.00K | 180.00K |
| Income Before Tax | -61.41M | -36.91M | -28.29M | -20.81M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -4.00K | 0.00 | 0.00 |
| Net Income | -61.41M | -36.91M | -28.29M | -20.81M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -6.42 | -3.86 | -3.44 | -2.53 |
| EPS Diluted | -6.42 | -3.86 | -3.44 | -2.53 |
| Weighted Avg Shares Out | 9.56M | 9.56M | 8.22M | 8.22M |
| Weighted Avg Shares Out (Dil) | 9.56M | 9.56M | 8.22M | 8.22M |
Hot Penny Stocks to Buy? 3 to Watch As CMPI Stock Shoots Up 320%
Here's what you need to know about trading penny stocks on April 19th The post Hot Penny Stocks to Buy? 3 to Watch As CMPI Stock Shoots Up 320% appeared first on Penny Stocks to Buy, Picks, News and Information...
Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types
Proposed ~$250 million all-cash acquisition strengthens Regeneron's portfolio of diverse and combinable immuno-oncology candidates Lead investigational asset vidutolimod is a potential best-in-class TLR9 agonist, with demonstrated clinical responses observed in PD-1 refractory melanoma as monotherapy Vidutolimod is currently being studied...
Investors Hoping for News at Cancer Meeting That Will Boost Share Prices
Given that developing biotechnology companies are more susceptible to swings in stock price than established ones, investors might want to keep an eye on happenings at next month's American Association for Cancer Research Annual Meeting in New Orleans. Of the...
Checkmate Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual Meeting
CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that it will present biomarker data...
Checkmate Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference
CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that Alan Fuhrman,...
Checkmate Pharmaceuticals to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
CAMBRIDGE, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that Alan Fuhrman,...
Checkmate Pharmaceuticals to Present at the Jefferies London Healthcare Conference
CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that James Wooldridge,...
Checkmate Pharmaceuticals Announces Webcast on Innate Immune Modulators and Vidutolimod (CMP-001)
Live presentation and Q&A moderated by Jefferies Equity Research on Tuesday, October 26, 2021 at 11:00am ET
Why BofA Turned Bullish On Checkmate Pharmaceuticals, But Slashed Price Target
Given the early clinical data on Checkmate Pharmaceuticals Inc's (NASDAQ:CMPI) vidutolimod, key opinion leaders remain “positively biased on its outlook,” according to BofA Securities. The Checkmate Pharmaceuticals Analyst: Jason Zemansky upgraded Checkmate Pharmaceuticals from Neutral to Buy and lowered the price target...
Checkmate Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that Barry Labinger,...
Source: https://incomestatements.info
Category: Stock Reports